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suffered from 21 attacks in total during the polysomnography. At-
tacks were not related to specific sleep stages (N1: 2/21 attacks, N2:
6/21 attacks, N3: 5/21 attacks, REM: 7/10 attacks).
eCH patients had longer latency (18.9 vs. 11.7 minutes, p<0.05) and
lower efficiency (84.4 vs. 86.5, p<0.05) compared with controls, but
fewer PLMs (0.67 vs. 1.30 hour-1, p<0.05). Finally, the sleep apnea
index was similar in both groups (9.63 vs. 7.76 hour-1, p=0.7674).
Conclusion: This is the first study that systematically investigates
eCH patients with full polysomnography in both bout and remission
and the largest study comparing eCH patients with controls. The ob-
served sleep disturbances were not associated with the bout but ra-
ther seem to be the manifestation of a persisting, underlying
pathology. Finally, the prevalence of sleep apnea was comparable in
all groups and attacks were not related to specific sleep stages.
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Background:
In migraine, the therapeutic preventive drug arsenal is varied. When
prescribing both Guidelines and patient characteristics are taken into
account. In Spain, the use of preventive therapies seems to be
heterogeneous.
The objective of this study was to evaluate real-life clinical prescrib-
ing practice amongst neurologists in Spain
Methods:
Observational descriptive study done with a survey by Neurologists
of the Spanish Neurological Society (SEN). Neurologists who partici-
pated were divided into Headache Specialists or not. The following
data was collected: socio-demographic data,; preventive treatment
and choices different migraine sub-types, and their personal percep-
tion of efficacy and tolerability to different drugs.
Results:
We analyzed 152 surveys from neurologists around our country.
From them: 43.4% were female, 53.3% <40 years, and 34.9% were in-
terested in headache .
In regards to preventive treatment choice; in chronic migraine topira-
mate (57%) amytriptiline (17.9%) and beta-blockers (14.6%), whereas
in episodic migraine the preferred drugs were beta-blockers (47.7%),
topiramate (21.5%) and amytriptiline (13.4%).
Regarding perceived efficacy, topiramate was considered the best
option in chronic migraine (42.7%) followed by onabotulinumtoxinA
(25.5%) and amitryptiline (22.4%). In episodic migraine, neurologist
preferred topiramate (43.7%) and beta-blockers (30.3%).
Regarding the duration of preventive therapy when improvement
was achieved, when treating episodic migraine 43.5% of the sur-
veyed neurologists recommended 3 months and 39.5% preferred 6
months. When they treated chronic migraine, 20.4% of neurologists
recommended 3 months, 42.1% 6 months, 12.5% 9 months and
22.4% preferred to maintain treatment during 12 months.
When considering onabotulinumtoxinA treatment, the number of
prior therapeutical failures was cero in 7.2% of surveyed, one in
5.9%, two in 44.1%, three in 30.9%, and four or more in 11.9%. The
increase of OnabotulinumtoxinA dose up to 195 UI was considered
by 51% of neurologists after a first ineffective procedure, by 42.2%
after two injections, and by 83% after a third infiltration. Surveyed
colleagues admitted to take into account in their decisions mainly
patient comorbidities (70.2%) rather than guidelines (13.9%).
Conclusions:
Initial management of Migraine among Spanish Neurologists is made
with the preventative drugs which are considered as first choices in
most of the guidelines. Management of episodic migraine differed
from chronic migraine, both in the order or drugs and the perception
of the most effective therapy.
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Objective To investigate the effect of the H1-antihistamine clemas-
tine on the migraine inducing abilities of pituitary adenylate cyclase
activating peptide-38 (PACAP38).
Methods We conducted a double-blind, randomized, placebo con-
trolled two-way cross-over study. Twenty migraine without aura pa-
tients were randomly allocated to receive bolus clemastine 2 mg (1
mg/ml) or bolus saline 2 ml intravenously over 2 min on two study
days. Following each bolus injection 10 pmol/kg/min of PACAP38
was administered intravenously over 20 min. We recorded migraine/
headache characteristics every 10 min until 90 min after infusion
start and collected blood to investigate mast cell degranulation and
the inflammation markers tryptase and tumor necrosis factor-alpha
(TNF-alpha) before and after infusion of PACAP38.
Results After clemastine pretreatment 5/20 participants developed a
migraine-like attack in response to a PACAP38 infusion compared to
9/20 after placebo pretreatment (P=0.288). Following clemastine pre-
treatment 15/20 participants reported headache in response to a
PACAP38 infusion, whereas 19/20 participants did so following pla-
cebo pretreatment (P=0.221). We found no difference in area under
the curve 12 h (AUC12h) for headache intensity between the two ex-
perimental days (P=0.481). We found no difference in AUC180min for
tryptase (P = 0.525) or TNF-alpha (P = 0.487) between clemastine
and placebo pretreatment days.
Conclusion H1-antihistamine, clemastine, failed to prevent migraine
or headache after PACAP38 infusion thus making a role for histamine
release or mast cell degranulation in PACAP38 induced migraine less
likely.
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Background
It is needed to identify the characteristics and the pressure-related
features of isolated cerebrospinal fluid hypertension for differentiat-
ing headache sufferers with isolated cerebrospinal fluid hypertension
from those with primary headache disorder.
Patients and Methods
In this prospective study patients with refractory chronic headaches
suspected of having cerebrospinal fluid-pressure elevation without
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